Jitladda Deerojanawong

Jitladda Deerojanawong

Auto-generated profile, based on publicly available information

Jitladda Deerojanawong

King Chulalongkorn Memorial Hospital Department of Pediatrics

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2015 in Indian Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
LKLalida Kongkiattikul
Lalida Kongkiattikul
SSSuchada Sritippayawan
Suchada Sritippayawan
SCSirinuch Chomtho
Sirinuch Chomtho
JDJitladda Deerojanawong
Jitladda Deerojanawong
NPNuanchan Prapphal
Nuanchan Prapphal

21 December 2017 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
TKThanakorn Kanjanapradap
Thanakorn Kanjanapradap
JDJitladda Deerojanawong
Jitladda Deerojanawong
SSSuchada Sritippayawan
Suchada Sritippayawan
NPNuanchan Prapphal
Nuanchan Prapphal

1 January 2021 in Asian Pacific Journal of Allergy and Immunology
Verified
Journal Article
Closed access
CDChalerat Direkwattanachai
Chalerat Direkwattanachai
CAChalermthai Aksilp
Chalermthai Aksilp
PCPantipa Chatchatee
Pantipa Chatchatee
OJOrathai Jirapongsananuruk
Orathai Jirapongsananuruk
HKHaruthai Kamalaporn
Haruthai Kamalaporn
JDJitladda Deerojanawong
Jitladda Deerojanawong
Background: Acute asthmatic exacerbation in children causes economic burdens both directly and indirectly. The GINA guideline does mention the use of inhaled or oral corticosteroids in the treatment of asthmatic exacerbation, it provides little practical guidance on the use of nebulized corticosteroid. Objective: To review and recommend the practical considerations in the use of nebulized corticosteroid in children with acute asthmatic exacerbation. Methods: This consensus was developed by a group of expert pediatricians in respiratory and allergy fields in Thailand. The recommendations were made based on a review of published studies and clinical opinions. The eligible studies were confined to those published in English, and randomized controlled trials and meta-analyses involving nebulized corticosteroids in asthmatic exacerbation in children aged between 1-18 years. Results: There were 13 randomized controlled-trial studies published from 1998 to 2017. Nine of the 13 studies com-pared nebulized with systemic corticosteroid conducted in moderate to severe exacerbation, while the remaining four compared nebulized corticosteroid with placebo conducted in mild to severe exacerbation. The admission rate was sig-nificantly lower in severe exacerbation (one study) and pooled four mild to severe exacerbation studies comparing with placebo (p 0.022). Other clinical parameters were significantly improved with nebulized corticosteroid such as clinical scores, systemic corticosteroid/bronchodilator use, or shorter ER stays. Only one study used fluticasone, while the other 12 studies conducted by budesonide (92.31%). Conclusion: Nebulized corticosteroid may offer an effective therapeutic option for the management of acute exacerba-tion of asthma in all severities. Nebulized budesonide is the preferred corticosteroid.

22 May 2017 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
JDJitladda Deerojanawong
Jitladda Deerojanawong
PLPitchaya Leartphichalak
Pitchaya Leartphichalak
ACAnkanee Chanakul
Ankanee Chanakul
SSSuchada Sritippayawan
Suchada Sritippayawan
RSRujipat Samransamruajkit
Rujipat Samransamruajkit

16 October 2024 in Pediatric Pulmonology
Verified
Journal Article
Closed access
SNSirapoom Niamsanit
Sirapoom Niamsanit
WBWicharn Boonjindasup
Wicharn Boonjindasup
SSSuchada Sritippayawan
Suchada Sritippayawan
JDJitladda Deerojanawong
Jitladda Deerojanawong
NPNuanchan Prapphal
Nuanchan Prapphal
WNWatit Niyomkarn
Watit Niyomkarn

1 January 2023 in Asian Pacific Journal of Allergy and Immunology
Verified
Journal Article
Open access
SCSasawan Chinratanapisit
Sasawan Chinratanapisit
PSPaskorn Sritipsukho
Paskorn Sritipsukho
ASAraya Satdhabudha
Araya Satdhabudha
KMKhlongtip Matchimmadamrong
Khlongtip Matchimmadamrong
JDJitladda Deerojanawong
Jitladda Deerojanawong
PCPantipa Chatchatee
Pantipa Chatchatee
Wheezing in preschool children is a common symptom. The study aimed to determine an incidence of recurrent wheezing among young children who had been hospitalized with acute wheezing after 12 months. Factors associated with recurrent wheezing were explored. A longitudinal study was conducted among 236 children, aged between 6 months and 5 years, who were hospitalized with acute wheezing in 4 hospitals located in Bangkok and adjacent provinces, Thailand. Demographics, house environments and clinical characteristic data were collected at entry. Serum specific IgE levels against common food and inhalant allergens and serum 25-hydroxyvitamin D (25OHD) concentrations were measured. At entry, the mean age was 24.4 months (SD = 15.7 months). Of 236 hospitalized children with acute wheezing, ninety-four cases (39.8%) were the first wheezing episode of life. By laboratory results, 197 (83.5%) and 56 (23.7%) children were atopic and had vitamin D insufficiency respectively. There were 195 cases completely followed for 12 months. One-year risk of emergency visits and hospitalization due to recurrent wheezing were 49.7% and 23.1% respectively. By multivariable analysis, being the second born child or more, vitamin D insufficiency, "ever wheeze", and allergic rhinitis were significantly associated with recurrent wheezing within 12 months with adjusted odds ratios of 2.5 (95% confidence interval: 1.3-5.3), 2.3 (95% confidence interval: 1.1-4.4), 1.9 (95% confidence interval: 1.2-3.5), and 1.6 (95% confidence interval: 1.3-2.9) respectively. Being the second born child or more, vitamin D insufficiency, ever wheeze, and allergic rhinitis were significant risks of recurrent wheezing.